Mumbai-based startup Esperer Nutrition has launched its office in London, United Kingdom in a move that aims to bridge the Onco Nutrition Gap in UK, Europe and US markets.
The move keeps the UK audience in mind and will tap into the Nutraceutical market of £275Bn globally and £4Bn is in the UK.
This move also resonates with the renewed focus on Nutraceutical Industry among a few others as per the UK Prime Minister’s Taskforce on Innovation, Growth and Regulatory Reform (TIGRR) announced in June 2021. The move will also see the organisation invest in research and development in the United Kingdom, in strategic collaborations with universities and trusts working in the areas of Nutraceuticals for Non-Communicable Diseases.
Raktim Chattopadhyay, Director for Esperer Nutrition UK, commented, “Reports have suggested that 1,600 children (up to the age of 15) in the UK are diagnosed with cancer each year with the most common are leukaemia (30 per cent), brain, CNS, and intracranial tumors (20 per cent) and lymphomas (11 per cent). Additionally, 28 million male adults in the UK are overweight or obese, which is fueling a diet related health crisis with spiraling rates of NCDs (non-communicable diseases). Our efforts with the launch of our innovation – DINI Axis (Diet Infection Nutrition Immunity) will aim to bridge the gap of malnutrition.”
The organisation will be investing in needful research in collaborations with various Trusts, Universities, Key Opinion Leaders as well as Actual Patients in addition to the investment in Research and Development.